Bearing this in mind, antihyperglycaemic agents with a lower risk of hypoglycaemia (in patients with type 1 diabetes: insulin analogues, especially second-generation basal insulin analogues; in patients with type 2 diabetes: SGLT-2-inhibitors, GLP-1-recepetor agonists, or DPP-4-inhibitors) should be preferred [45,46]. This evidence concerns the gene INS and type 2 diabetes mellitus.